Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome
Phase 2
Recruiting
- Conditions
- Retinopathy of Prematurity
- Registration Number
- NCT00346814
- Lead Sponsor
- Asociación para Evitar la Ceguera en México
- Brief Summary
Purpose:Retinopathy of prematurity (ROP) continues tobe a major cause of blindness in children. Although ablation of the retina with laser or cryotherapy reduces the incidence of blindness by suppressing the neovascular phase of ROP the visual outcomes after treatment are often poor. Vascular endothelial growth factor(VEGF) has an important role in the pathogenesis of ROP and inhibition of VEGF expression in the neovascular phase might prevent destructive neovascularization in ROP. The aim of this study is to determine the safety and efficacy of intravitreal bevacizumab in the treatment of retinopathy of prematurity
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Retinopathy of prematurity stages III, IV and V in which we can not treat with laser o cryotherAPY
Exclusion Criteria
- PATIENTS THAT COULD BE TREATED WITH CRYOTHERAPY OR LASER
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Clinical appearance
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Asociación para Evitar la Ceguera en México Hospital "Luis Sanchez Bulnes"
🇲🇽Mexico City, Mexico DF, Mexico